Planning For Scale From The Start: Where Early Development Decisions Create Commercial Risk

A well-defined late-stage scale-up plan is important, but it cannot address every challenge that may emerge during commercialization. Decisions made much earlier in development can have consequences that remain hidden until a program reaches scale-up, technology transfer, or commercial manufacturing. For emerging biopharma companies, recognizing these downstream implications early can help avoid costly adjustments and build a stronger foundation for launch.

This on-demand webinar explores how companies can maintain lean clinical development and manufacturing operations while preparing for future commercial requirements. The discussion examines how accelerated development timelines can be supported by connected manufacturing planning that considers long-term scale, production capacity, and supply needs. It also highlights the importance of aligning development, manufacturing, quality, and supply chain teams from the outset, rather than addressing their respective requirements in isolation as a program advances.

By bringing these functions together earlier, companies can better anticipate operational challenges, support launch readiness, and build greater resilience into their supply strategies. Watch the webinar to explore which early-stage decisions can have the greatest impact on commercialization and how integrated planning can help prepare programs for the transition from clinical development to commercial supply.